Motivation to pursue anti-TNFα treatment in patients with Crohn's disease - the SPACE motivation study.
Identifieur interne : 000146 ( Main/Corpus ); précédent : 000145; suivant : 000147Motivation to pursue anti-TNFα treatment in patients with Crohn's disease - the SPACE motivation study.
Auteurs : Ferdinando D'Amico ; Laurent Peyrin-Biroulet ; Luc Vandromme ; Yoram Bouhnik ; Patrick Faure ; Stéphane Nahon ; Hervé Hagege ; Xavier Hebuterne ; Salim Benkhalifa ; Maria NachurySource :
- Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver [ 1878-3562 ] ; 2020.
Abstract
BACKGROUND
Crohn's disease (CD) is a chronic disorder requiring long-term treatment. However, up to 20% of patients interrupt temporarily or permanently anti-TNFα. Primary aim was to identify internal and external factors influencing patient's motivation to pursue anti-TNFα in active CD.
METHODS
This was a French, multicentre, prospective study enrolling CD patients on anti-TNFα therapy since more than 3 months. Patients completed the Satisfaction of Patients with Crohn's Disease questionnaire (SPACE-Q) and other patient-reported-outcome tools at inclusion visit, and after 6 and 12 months.
RESULTS
A total of 274 patients were included: 146 (53.3%) received adalimumab, while 128 (46.7%) infliximab. Most patients (78%) were still treated with anti-TNFα 12 months after enrolment. Patients' perception of necessity (p = 0.01) and concerns (p<0.0001) regarding medication, evaluated through the Belief about Medicines Questionnaire (BMQ), and expectation confirmation towards treatment convenience (p = 0.02), towards efficacy (p = 0.04), and treatment satisfaction (p = 0.03) according to SPACE-Q, correlated with motivation to pursue treatment. Patients with higher treatment satisfaction (p = 0.0004), stronger belief in treatment necessity (p<0.0001) and fewer concerns (p = 0.0002) were more likely to be very motivated.
CONCLUSION
Treatment satisfaction, treatment necessity, and concerns are correlated to motivation to pursue anti-TNFα. Specific questions focused on these patients' perceptions could help physicians to identify patients at risk of non-adherence and prevent therapy interruption.
DOI: 10.1016/j.dld.2020.05.032
PubMed: 32532602
Links to Exploration step
pubmed:32532602Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Motivation to pursue anti-TNFα treatment in patients with Crohn's disease - the SPACE motivation study.</title><author><name sortKey="D Amico, Ferdinando" sort="D Amico, Ferdinando" uniqKey="D Amico F" first="Ferdinando" last="D'Amico">Ferdinando D'Amico</name><affiliation><nlm:affiliation>Department of Biomedical Sciences, Humanitas University, Milan, Italy; Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, 1 Allée du Morvan, 54511 Vandoeuvre-lès-Nancy, France.</nlm:affiliation></affiliation></author><author><name sortKey="Peyrin Biroulet, Laurent" sort="Peyrin Biroulet, Laurent" uniqKey="Peyrin Biroulet L" first="Laurent" last="Peyrin-Biroulet">Laurent Peyrin-Biroulet</name><affiliation><nlm:affiliation>Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, 1 Allée du Morvan, 54511 Vandoeuvre-lès-Nancy, France. Electronic address: peyrinbiroulet@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Vandromme, Luc" sort="Vandromme, Luc" uniqKey="Vandromme L" first="Luc" last="Vandromme">Luc Vandromme</name><affiliation><nlm:affiliation>Polyclinique de Courlancy, Hépato-Gastro-Entérologie, Reims, France.</nlm:affiliation></affiliation></author><author><name sortKey="Bouhnik, Yoram" sort="Bouhnik, Yoram" uniqKey="Bouhnik Y" first="Yoram" last="Bouhnik">Yoram Bouhnik</name><affiliation><nlm:affiliation>Hôpital Beaujon, Gastroentérologie, MICI et Assistance Nutritive, APHP, Université Paris-Diderot, Clichy, France.</nlm:affiliation></affiliation></author><author><name sortKey="Faure, Patrick" sort="Faure, Patrick" uniqKey="Faure P" first="Patrick" last="Faure">Patrick Faure</name><affiliation><nlm:affiliation>Clinique Pasteur, Hépato-Gastro-Entérologie, 31076 Toulouse cedex 3, France.</nlm:affiliation></affiliation></author><author><name sortKey="Nahon, Stephane" sort="Nahon, Stephane" uniqKey="Nahon S" first="Stéphane" last="Nahon">Stéphane Nahon</name><affiliation><nlm:affiliation>Centre Hospitalier Intercommunal, Hépato-Gastro-Entérologie, Le Raincy Montfermeil, France.</nlm:affiliation></affiliation></author><author><name sortKey="Hagege, Herve" sort="Hagege, Herve" uniqKey="Hagege H" first="Hervé" last="Hagege">Hervé Hagege</name><affiliation><nlm:affiliation>Centre Hospitalier Intercommunal, Hépato-Gastro-Entérologie, Créteil, France.</nlm:affiliation></affiliation></author><author><name sortKey="Hebuterne, Xavier" sort="Hebuterne, Xavier" uniqKey="Hebuterne X" first="Xavier" last="Hebuterne">Xavier Hebuterne</name><affiliation><nlm:affiliation>Service de gastro-entérologie et Nutrition, CHU de Nice et Université Côte d'Azur, Nice, France.</nlm:affiliation></affiliation></author><author><name sortKey="Benkhalifa, Salim" sort="Benkhalifa, Salim" uniqKey="Benkhalifa S" first="Salim" last="Benkhalifa">Salim Benkhalifa</name><affiliation><nlm:affiliation>AbbVie France, Rungis, France.</nlm:affiliation></affiliation></author><author><name sortKey="Nachury, Maria" sort="Nachury, Maria" uniqKey="Nachury M" first="Maria" last="Nachury">Maria Nachury</name><affiliation><nlm:affiliation>CHU Lille, Service des maladies de l'appareil digestif, F-59000 Lille, France.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32532602</idno><idno type="pmid">32532602</idno><idno type="doi">10.1016/j.dld.2020.05.032</idno><idno type="wicri:Area/Main/Corpus">000146</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000146</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Motivation to pursue anti-TNFα treatment in patients with Crohn's disease - the SPACE motivation study.</title><author><name sortKey="D Amico, Ferdinando" sort="D Amico, Ferdinando" uniqKey="D Amico F" first="Ferdinando" last="D'Amico">Ferdinando D'Amico</name><affiliation><nlm:affiliation>Department of Biomedical Sciences, Humanitas University, Milan, Italy; Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, 1 Allée du Morvan, 54511 Vandoeuvre-lès-Nancy, France.</nlm:affiliation></affiliation></author><author><name sortKey="Peyrin Biroulet, Laurent" sort="Peyrin Biroulet, Laurent" uniqKey="Peyrin Biroulet L" first="Laurent" last="Peyrin-Biroulet">Laurent Peyrin-Biroulet</name><affiliation><nlm:affiliation>Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, 1 Allée du Morvan, 54511 Vandoeuvre-lès-Nancy, France. Electronic address: peyrinbiroulet@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Vandromme, Luc" sort="Vandromme, Luc" uniqKey="Vandromme L" first="Luc" last="Vandromme">Luc Vandromme</name><affiliation><nlm:affiliation>Polyclinique de Courlancy, Hépato-Gastro-Entérologie, Reims, France.</nlm:affiliation></affiliation></author><author><name sortKey="Bouhnik, Yoram" sort="Bouhnik, Yoram" uniqKey="Bouhnik Y" first="Yoram" last="Bouhnik">Yoram Bouhnik</name><affiliation><nlm:affiliation>Hôpital Beaujon, Gastroentérologie, MICI et Assistance Nutritive, APHP, Université Paris-Diderot, Clichy, France.</nlm:affiliation></affiliation></author><author><name sortKey="Faure, Patrick" sort="Faure, Patrick" uniqKey="Faure P" first="Patrick" last="Faure">Patrick Faure</name><affiliation><nlm:affiliation>Clinique Pasteur, Hépato-Gastro-Entérologie, 31076 Toulouse cedex 3, France.</nlm:affiliation></affiliation></author><author><name sortKey="Nahon, Stephane" sort="Nahon, Stephane" uniqKey="Nahon S" first="Stéphane" last="Nahon">Stéphane Nahon</name><affiliation><nlm:affiliation>Centre Hospitalier Intercommunal, Hépato-Gastro-Entérologie, Le Raincy Montfermeil, France.</nlm:affiliation></affiliation></author><author><name sortKey="Hagege, Herve" sort="Hagege, Herve" uniqKey="Hagege H" first="Hervé" last="Hagege">Hervé Hagege</name><affiliation><nlm:affiliation>Centre Hospitalier Intercommunal, Hépato-Gastro-Entérologie, Créteil, France.</nlm:affiliation></affiliation></author><author><name sortKey="Hebuterne, Xavier" sort="Hebuterne, Xavier" uniqKey="Hebuterne X" first="Xavier" last="Hebuterne">Xavier Hebuterne</name><affiliation><nlm:affiliation>Service de gastro-entérologie et Nutrition, CHU de Nice et Université Côte d'Azur, Nice, France.</nlm:affiliation></affiliation></author><author><name sortKey="Benkhalifa, Salim" sort="Benkhalifa, Salim" uniqKey="Benkhalifa S" first="Salim" last="Benkhalifa">Salim Benkhalifa</name><affiliation><nlm:affiliation>AbbVie France, Rungis, France.</nlm:affiliation></affiliation></author><author><name sortKey="Nachury, Maria" sort="Nachury, Maria" uniqKey="Nachury M" first="Maria" last="Nachury">Maria Nachury</name><affiliation><nlm:affiliation>CHU Lille, Service des maladies de l'appareil digestif, F-59000 Lille, France.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver</title><idno type="eISSN">1878-3562</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Crohn's disease (CD) is a chronic disorder requiring long-term treatment. However, up to 20% of patients interrupt temporarily or permanently anti-TNFα. Primary aim was to identify internal and external factors influencing patient's motivation to pursue anti-TNFα in active CD.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>This was a French, multicentre, prospective study enrolling CD patients on anti-TNFα therapy since more than 3 months. Patients completed the Satisfaction of Patients with Crohn's Disease questionnaire (SPACE-Q) and other patient-reported-outcome tools at inclusion visit, and after 6 and 12 months.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>A total of 274 patients were included: 146 (53.3%) received adalimumab, while 128 (46.7%) infliximab. Most patients (78%) were still treated with anti-TNFα 12 months after enrolment. Patients' perception of necessity (p = 0.01) and concerns (p<0.0001) regarding medication, evaluated through the Belief about Medicines Questionnaire (BMQ), and expectation confirmation towards treatment convenience (p = 0.02), towards efficacy (p = 0.04), and treatment satisfaction (p = 0.03) according to SPACE-Q, correlated with motivation to pursue treatment. Patients with higher treatment satisfaction (p = 0.0004), stronger belief in treatment necessity (p<0.0001) and fewer concerns (p = 0.0002) were more likely to be very motivated.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>Treatment satisfaction, treatment necessity, and concerns are correlated to motivation to pursue anti-TNFα. Specific questions focused on these patients' perceptions could help physicians to identify patients at risk of non-adherence and prevent therapy interruption.</p></div></front></TEI><pubmed><MedlineCitation Status="In-Data-Review" Owner="NLM"><PMID Version="1">32532602</PMID><DateRevised><Year>2020</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3562</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver</Title><ISOAbbreviation>Dig Liver Dis</ISOAbbreviation></Journal><ArticleTitle>Motivation to pursue anti-TNFα treatment in patients with Crohn's disease - the SPACE motivation study.</ArticleTitle><Pagination><MedlinePgn>995-1001</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1590-8658(20)30238-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.dld.2020.05.032</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Crohn's disease (CD) is a chronic disorder requiring long-term treatment. However, up to 20% of patients interrupt temporarily or permanently anti-TNFα. Primary aim was to identify internal and external factors influencing patient's motivation to pursue anti-TNFα in active CD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a French, multicentre, prospective study enrolling CD patients on anti-TNFα therapy since more than 3 months. Patients completed the Satisfaction of Patients with Crohn's Disease questionnaire (SPACE-Q) and other patient-reported-outcome tools at inclusion visit, and after 6 and 12 months.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 274 patients were included: 146 (53.3%) received adalimumab, while 128 (46.7%) infliximab. Most patients (78%) were still treated with anti-TNFα 12 months after enrolment. Patients' perception of necessity (p = 0.01) and concerns (p<0.0001) regarding medication, evaluated through the Belief about Medicines Questionnaire (BMQ), and expectation confirmation towards treatment convenience (p = 0.02), towards efficacy (p = 0.04), and treatment satisfaction (p = 0.03) according to SPACE-Q, correlated with motivation to pursue treatment. Patients with higher treatment satisfaction (p = 0.0004), stronger belief in treatment necessity (p<0.0001) and fewer concerns (p = 0.0002) were more likely to be very motivated.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Treatment satisfaction, treatment necessity, and concerns are correlated to motivation to pursue anti-TNFα. Specific questions focused on these patients' perceptions could help physicians to identify patients at risk of non-adherence and prevent therapy interruption.</AbstractText><CopyrightInformation>Copyright © 2020 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>D'Amico</LastName><ForeName>Ferdinando</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Milan, Italy; Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, 1 Allée du Morvan, 54511 Vandoeuvre-lès-Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peyrin-Biroulet</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, 1 Allée du Morvan, 54511 Vandoeuvre-lès-Nancy, France. Electronic address: peyrinbiroulet@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandromme</LastName><ForeName>Luc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Polyclinique de Courlancy, Hépato-Gastro-Entérologie, Reims, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouhnik</LastName><ForeName>Yoram</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Hôpital Beaujon, Gastroentérologie, MICI et Assistance Nutritive, APHP, Université Paris-Diderot, Clichy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faure</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinique Pasteur, Hépato-Gastro-Entérologie, 31076 Toulouse cedex 3, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nahon</LastName><ForeName>Stéphane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre Hospitalier Intercommunal, Hépato-Gastro-Entérologie, Le Raincy Montfermeil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagege</LastName><ForeName>Hervé</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Centre Hospitalier Intercommunal, Hépato-Gastro-Entérologie, Créteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hebuterne</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Service de gastro-entérologie et Nutrition, CHU de Nice et Université Côte d'Azur, Nice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benkhalifa</LastName><ForeName>Salim</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>AbbVie France, Rungis, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nachury</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CHU Lille, Service des maladies de l'appareil digestif, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Dig Liver Dis</MedlineTA><NlmUniqueID>100958385</NlmUniqueID><ISSNLinking>1590-8658</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-tumor necrosis factor α</Keyword><Keyword MajorTopicYN="N">Crohn's disease</Keyword><Keyword MajorTopicYN="N">Motivation</Keyword><Keyword MajorTopicYN="N">Satisfaction of patients with Crohn's disease questionnaire (SPACE-Q)</Keyword><Keyword MajorTopicYN="N">Treatment adherence</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest F. D'Amico declares no conflict of interest. L. Peyrin-Biroulet has served as a speaker, consultant and advisory board member for Merck, Abbvie, Janssen, Genentech, Mitsubishi, Ferring, Norgine, Tillots, Vifor, Hospira/Pfizer, Celltrion, Takeda, Biogaran, Boerhinger-Ingelheim, Lilly, HAC- Pharma, Index Pharmaceuticals, Amgen, Sandoz, For- ward Pharma GmbH, Celgene, Biogen, Lycera, Samsung Bioepis, Theravance. L. Vandromme has served as consultant for Abbvie Laboratories. Y. Bounhik received consulting and lecture fees from AbbVie, Biogaran, Biogen, Boehringer Ingelheim, Celgene, Ferring, Gilead, Hospira, Janssen, Mayoli Spindler, MSD, Norgine, Pfizer, Roche, Samsung Bioepis, Sandoz, Sanofi, Shire, Takeda, UCB. P.Faure has served as consultant for Abbvie Laboratories. S. Nahon has served as consultant for Abbvie Laboratories. H. Hagège has served as consultant for Abbvie, Alfasigma, Ferring, Janssen, Norgine, Mayoly Spindler, MSD, Takeda, Tillotts. X. Hebuterne has served on advisory boards for Abbvie, Abivax, Alphasigma, ARARD, Arkopharma, Astellas, Baxter, Bristol Myers Squibb, Cellgen, Gilead, Eli Lilly, Enterome, Ferring, Fresenius-Kabi, InDex Pharmaceuticals, Janssen, MSD, Nutricia, Pfizer, Roche, Sanofi-Advantis, SAlix, Sangamo, Takeda, Theravance, Tillots. S. Benkhalifa is employee of Abbvie. M. Nachury has served as consultant for Abbvie, Adacyte, Amgen, Biogen, Ferring, Janssen, Mayoli-Spindler, MSD, and Takeda.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>02</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>04</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>05</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32532602</ArticleId><ArticleId IdType="pii">S1590-8658(20)30238-3</ArticleId><ArticleId IdType="doi">10.1016/j.dld.2020.05.032</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/WillowV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000146 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000146 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= WillowV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32532602
|texte= Motivation to pursue anti-TNFα treatment in patients with Crohn's disease - the SPACE motivation study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32532602" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a WillowV1
| This area was generated with Dilib version V0.6.37. |  |